1.40
price up icon3.70%   0.05
after-market Dopo l'orario di chiusura: 1.40
loading
Precedente Chiudi:
$1.35
Aprire:
$1.37
Volume 24 ore:
376.63K
Relative Volume:
2.95
Capitalizzazione di mercato:
$51.20M
Reddito:
-
Utile/perdita netta:
$-9.16M
Rapporto P/E:
-2.4561
EPS:
-0.57
Flusso di cassa netto:
$-8.75M
1 W Prestazione:
+17.65%
1M Prestazione:
+44.36%
6M Prestazione:
+10.24%
1 anno Prestazione:
+19.66%
Intervallo 1D:
Value
$1.31
$1.40
Intervallo di 1 settimana:
Value
$1.20
$1.40
Portata 52W:
Value
$0.75
$1.6899

Renovorx Inc Stock (RNXT) Company Profile

Name
Nome
Renovorx Inc
Name
Telefono
408-800-2649
Name
Indirizzo
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Name
Dipendente
10
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-15
Name
Ultimi documenti SEC
Name
RNXT's Discussions on Twitter

Confronta RNXT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RNXT
Renovorx Inc
1.40 43.52M 0 -9.16M -8.75M -0.57
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Renovorx Inc Borsa (RNXT) Ultime notizie

pulisher
May 29, 2025

New U.S. Patent Issued to RenovoRx for Drug Therapy Platform - Medical Product Outsourcing

May 29, 2025
pulisher
May 25, 2025

RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment - simplywall.st

May 25, 2025
pulisher
May 22, 2025

Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 21, 2025

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 21, 2025
pulisher
May 20, 2025

RenovoRx (NASDAQ:RNXT) Receives “Buy” Rating from HC Wainwright - Defense World

May 20, 2025
pulisher
May 20, 2025

RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook - TipRanks

May 20, 2025
pulisher
May 19, 2025

RenovoRx (RNXT): HC Wainwright Reiterates Buy Rating with $3.00 Target | RNXT Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript - MSN

May 18, 2025
pulisher
May 17, 2025

RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating - TipRanks

May 17, 2025
pulisher
May 16, 2025

RenovoRx Earnings Call: Positive Outlook Amid Growth - TipRanks

May 16, 2025
pulisher
May 16, 2025

RenovoRx Inc (RNXT) Q1 2025 Earnings: EPS of -$0.08 Beats Estima - GuruFocus

May 16, 2025
pulisher
May 16, 2025

RenovoRx earnings beat, revenue fell short of estimates - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

RenovoRx Reports Promising Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations - Investing.com

May 15, 2025
pulisher
May 15, 2025

RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - BioSpace

May 15, 2025
pulisher
May 15, 2025

RenovoRx Q1 2025 Earnings Call Transcript - MarketBeat

May 15, 2025
pulisher
May 15, 2025

RenovoRx reports Q1 EPS (8c), consensus (8c) - TipRanks

May 15, 2025
pulisher
May 15, 2025

RenovoRx (RNXT) Reports Strong Q1 Revenue Surpassing Expectations | RNXT Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

RenovoRx Reports Strong Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - BioSpace

May 14, 2025
pulisher
May 08, 2025

RenovoRx Expands RenovoCath Production to Meet an Increasing Demand - Zenopa

May 08, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Makes New Investment in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World

May 08, 2025
pulisher
May 06, 2025

RenovoRx Ramps Up U.S. Production of RenovoCath Devices - Medical Product Outsourcing

May 06, 2025
pulisher
May 06, 2025

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire

May 06, 2025
pulisher
May 02, 2025

RenovoRx (RNXT) Projected to Post Earnings on Friday - Defense World

May 02, 2025
pulisher
May 01, 2025

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - BioSpace

May 01, 2025
pulisher
Apr 30, 2025

CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer - Curetoday

Apr 30, 2025
pulisher
Apr 30, 2025

Ascendiant Capital Markets Forecasts Strong Price Appreciation for RenovoRx (NASDAQ:RNXT) Stock - The AM Reporter

Apr 30, 2025
pulisher
Apr 29, 2025

RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer T - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

RenovoRx (RNXT) Advances Phase III Trial for Pancreatic Cancer Treatment | RNXT Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial - Business Wire

Apr 29, 2025
pulisher
Apr 29, 2025

RenovoRx (NASDAQ:RNXT) Price Target Raised to $11.00 at Ascendiant Capital Markets - Defense World

Apr 29, 2025
pulisher
Apr 27, 2025

RenovoRx Reports Initial Revenue and Clinical Trial Progress - MSN

Apr 27, 2025
pulisher
Apr 17, 2025

RenovoRx CMO Makes Bold Stock Purchase! - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

Jersey Shore debuts N.J.’s first TAMP cancer therapy - ROI-NJ

Apr 17, 2025
pulisher
Apr 16, 2025

RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace

Apr 16, 2025
pulisher
Apr 16, 2025

RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan

Apr 16, 2025

Renovorx Inc Azioni (RNXT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):